Turnover: ()
Country: France
Biotechnology, drug development
News
Soda disease: Inventiva expands in Asia | Impact of soda consumption in Asia. 06/10/2023
- Inventiva was founded 11 years ago.
- It has 115 employees, including some 50 researchers.
- It has been listed on the stock exchange since 2017 and on Nasdaq since 2020.
- The global market for their field of activity (treatment of "soda disease") is estimated at between $15 and $30 billion, and the disease affects 10% of the adult population in the United States.
- The partnership signed with Sino Biopharm in September 2022 resulted in an initial payment of $12 million, with the potential to reach up to $290 million in milestone payments.
- The contract recently signed with Hepalys Pharma for Japan and South Korea provides for an initial receipt of $10 million for a total of up to $231 million in milestone payments, plus royalties of 10% to 20% on sales.
- Inventiva holds a 30% stake in Hepalys Pharma.
Financial Data
DUNS: 537530255
Legal Name: INVENTIVA
Address: 50 RUE DE DIJON , 21121 DAIX
Capital: 421 342 EUR
Financial Data:
| Year | Turnover (€) | Net Profit (€) | Fiscal Year End | Fiscal Year Duration |
|---|---|---|---|---|
| 2020 | 372 000 EUR | -31 578 000 EUR | 31/12/2020 | 12 |
| 2019 | 4 777 870 EUR | -30 802 920 EUR | 31/12/2019 | 12 |
| 2018 | 3 303 010 EUR | -31 956 860 EUR | 31/12/2018 | 12 |
| 2017 | 6 520 820 EUR | -10 135 460 EUR | 31/12/2017 | 12 |
| 2016 | 9 445 640 EUR | 5 595 740 EUR | 31/12/2016 | 12 |
Company Managers:
| Position | First Name | Last Name | Age | |
|---|---|---|---|---|
| Directeur général | Frédéric | CREN | 58 |